Background: Although colorectal adenomas serve as prime target for colorectal cancer (CRC) surveillance in other high-risk groups, data on adenoma risk after childhood cancer are lacking. We evaluated the risk of histologically confirmed colorectal adenomas among childhood cancer survivors. A secondary aim was to assess CRC risk. Methods: The DCOG-LATER cohort study includes five-year Dutch childhood cancer survivors and a sibling comparison group (n ¼ 883). Colorectal tumors were identified from the population-based Dutch Pathology Registry (PALGA). We calculated cumulative incidences of adenomas/CRCs for survivors and siblings. For adenomas, multivariable Cox regression models were used to evaluate potential risk factors. All statistical tests were two-sided. Results: Among 5843 five-year survivors (median follow-up ¼ 24.9 years), 78 individuals developed an adenoma. Cumulative incidence by age 45 years was 3.6% (95% confidence interval [CI] ¼ 2.2% to 5.6%) after abdominopelvic radiotherapy (AP-RT; 49 cases) vs 2.0% (95% CI ¼ 1.3% to 2.8%) among survivors without AP-RT (28 cases; P difference ¼ .07) and vs 1.0% (95% CI ¼ 0.3% to 2.6%) among siblings (6 cases 
95% CI ¼ 8.80 to 83.58), and family history of early-onset CRC (HR ¼ 20.46, 95% CI ¼ 8.10 to 51.70). Procarbazine was statistically significantly associated among survivors without AP-RT/TBI (HR ¼ 2.71, 95% CI ¼ 1.28 to 5.74). Thirteen CRCs occurred. Conclusion: We provide evidence for excess risk of colorectal adenomas and CRCs among childhood cancer survivors. Adenoma risk factors include AP-RT, TBI, cisplatin, and procarbazine. Hepatoblastoma (familial adenomatous polyposisassociated) and family history of early-onset CRC were confirmed as strong risk factors. A full benefit-vs-harm evaluation of CRC screening among high-risk childhood cancer survivors warrants consideration.
In recent years, evidence has mounted for an elevated incidence of colorectal cancer (CRC) among (young) adults who received high-dose abdominal radiotherapy decades earlier and, perhaps, also among those who received alkylating agent-based chemotherapy (1) (2) (3) (4) . These findings have spurred debate on the need for early detection programs among childhood cancer survivors (1-4) to find CRC precursors, that is, adenoma or earlystage CRC amenable to curative treatment (5) (6) (7) . A recent study of early colonoscopic screening (age 35-49 years) among 54 childhood cancer survivors treated with high-dose abdominal radiotherapy revealed an adenomatous polyp prevalence comparable with that among the average-risk population age 50 years or older (8) . To our knowledge, there have been no published data on the risk of and treatment-related risk factors for colorectal adenomas among childhood cancer survivors not involved in colorectal tumor surveillance programs.
In the general population and among individuals with cancer susceptibility syndromes, most CRCs are preceded by adenomas (9, 10) . Timely removal of adenomas reduces CRC incidence and mortality (11, 12) , providing the rationale for CRC screening in these settings (5) (6) (7) .
We aimed to determine the risk of histologically confirmed colorectal adenomas and cancers in a large cohort of five-year childhood cancer survivors not subject to systematic colorectal tumor screening and a sibling comparison group. Moreover, we quantified contributions of abdominopelvic radiotherapy, specific chemotherapeutic agents, and indicators of colorectal tumor predisposition in the etiology of adenomas.
Methods

Study Cohort
The DCOG-LATER cohort includes five-year survivors of childhood cancer originally diagnosed between January 1, 1963, and December 31, 2001 , younger than age 18 years in one of seven Dutch pediatric oncology and stem cell transplant centers, as reported previously (13) . The study protocol was declared exempt from review of medical intervention research by institutional review boards of all participating centers.
Information on Diagnosis, Treatment, and Family History of Colorectal Cancer
Details on prior cancer diagnosis and treatment for primary tumor and any recurrences were collected from original medical files (13) . Here, we further specified abdominopelvic radiation exposure by estimating the colorectal tract volume directly exposed to radiation. A pediatric radiation oncologist (WD) and a radiation technologist (JK) determined the estimated proportion of total colorectal volume exposed based on the childhood cancer-specific coded treatment fields. Also, anatomy/position information of the colorectum was used, based on specific experience, anatomy text books, and a sample of available radiotherapy simulation films from fields involving the abdomen (Supplementary Table 1 , available online). Discrepancies were discussed (JCT) until consensus was achieved. Total body irradiation (TBI) was evaluated separately. Information on family history of early-onset CRC (CRC before age 50 years in firstdegree relatives) was collected in the 2013-2014 DCOG-LATER questionnaire survey and from medical records.
Vital Status and Colorectal Tumor Outcome Ascertainment
Vital status and emigration status for all survivors were obtained from the Municipal Person Records Database, linkage to the Central Office of Genealogy, or from the last known municipality of residence (13) . Colorectal tumors were identified by linkage with the nationwide network and registry of histo-and cytopathology in the Netherlands (PALGA), which was established in 1970 and which attained full nationwide coverage in 1990 (14) . Linkage was based on family name, sex, and birth date. We included all pathology excerpts with PALGA codes for colorectal adenomas and cancers (detailed in Supplementary  Table 2 , available online) in the period January 1, 1990, to January 9, 2017. For all adenomas, we sought medical file review in the DCOG-LATER academic centers to retrieve the indication for colonoscopy, coded as follows: 1) specific colorectal tumorrelated symptoms; 2) screening or surveillance colonoscopy because of a (possible) genetic predisposition for developing colorectal tumors; 3) screening or surveillance colonoscopy for other reasons; 4) accidental finding on imaging/colonoscopy for reasons other than a suspected colorectal tumor.
Eligible Study Population Survivors and Siblings
From the DCOG-LATER cohort (6165 five-year survivors), we excluded individuals who opposed use of health care data (n ¼ 152) and those who died, emigrated, or were lost to followup prior to 1990 (n ¼ 170) ( Figure S1 ). Survivors who participated in the 2013-2014 questionnaire survey (n ¼ 3172) were asked to invite their respective siblings. In total, 883 of 1663 (53%) approached siblings were eligible for this study, and colorectal adenomas and cancers were ascertained as described above.
Statistical Analyses
Time at risk started five years after childhood cancer diagnosis or January 1, 1990 (date full nationwide coverage PALGA), whichever came last, and ended at the date of diagnosis of the first adenoma, date of death, date of emigration, date of loss to follow-up, or end of study (January 9, 2017), whichever came first. To describe heterogeneity in the cohort, the distribution of person-years and the crude adenoma rate/10 000 person-years were graphically depicted by childhood cancer type, stratified by age or by radiotherapy to the colorectal area (abdominopelvic radiotherapy/TBI). Cumulative incidence of histologically confirmed adenomas was estimated, treating death as a competing risk. Cumulative incidences were compared between (subgroups of) survivors and siblings with pairwise Pepe-Mori tests (15) . Multivariable Cox proportional hazards models were used to examine the effect of potential risk factors on subsequent adenoma risk (as detailed in the Supplementary Methods and Supplementary Table 3, available online). We chose attained age as the time scale to take into account expected variation in colon adenoma risk with increasing age (16) . Although the main focus was on treatment factors, we added indicator variables for hepatoblastoma and medulloblastoma to the final model to ascertain the anticipated influence of genetic susceptibility to colorectal tumors because these childhood tumors cluster among individuals affected by familial adenomatous polyposis (FAP) (17) . We evaluated the proportional hazards assumption by visual inspection of log-minus-log survival curves and Schoenfeld residuals vs attained age. We calculated standardized incidence ratios (SIRs) and excess absolute risks per 10 000 person-years of follow-up (EARs) for CRC. Expected numbers were based on age-, sex-, and calendar year-specific rates from the Netherlands Cancer Registry (13, 18) . All analyses were performed using Stata, version 13 (Stata Statistical Software, Release 13, StataCorp., College Station, TX). All statistical tests were two-sided. For all analyses, a P value of less than .05 was considered statistically significant.
Results
Cohort Characteristics
This analysis included 5843 five-year survivors (97.4% with complete follow-up during 1990-2017) who contributed 112 157 person-years at risk. The median time since childhood cancer diagnosis was 24.9 years (range ¼ 5.0-53.9 years), and the median attained age at end of follow-up was 32.4 years (range ¼ 5.8-69.2 years) for survivors and 32.2 years (range ¼ 11.4-73.3 years) for siblings. In total, 78 (1.3%) survivors developed at least one adenoma compared with six of 883 (0.7%) siblings (Table 1) . Survivors with adenoma had a higher attained age at end of follow-up than the cohort as a whole. More than half of the survivors with an adenoma developed multiple adenomas, and six patients (7.7%) developed more than 10 adenomas. Compared with the eligible cohort, patients with adenoma were seemingly more often diagnosed with childhood cancer prior to 1980 and were more likely to have received radiotherapy to the colorectal area, procarbazine, and cisplatin ( Table 2) . 
Cohort Distribution of Age and Abdominopelvic Radiotherapy/TBI
The adenoma rate appeared to be highest among individuals age 40 years or older (red bars in Supplementary Figure 2A , available online). In all, survivors of renal tumors seemed to be the most likely to have received abdominopelvic radiotherapy/ TBI (40.4%, gray bars in Supplementary Figure 2B , available online). Moreover, survivors with abdominopelvic radiotherapy/ TBI appeared to have higher adenoma rates than survivors without such treatments, in particular following leukemia, renal tumors, and sarcoma (red bars in Supplementary Figure 2B , available online).
Cumulative Incidence Colorectal Adenoma
The cumulative incidence of histologically confirmed adenomas by age 45 years was 3.6% (95% confidence interval [CI] ¼ 2.2% to 5.6%) for survivors who had radiotherapy to the colorectal area (including TBI), 2.0% (95% CI ¼ 1.3% to 2.8%) for those without such treatments, and 1.0% (95% CI ¼ 0.3% to 2.6%) for siblings ( Figure 1 ). Among survivors with radiotherapy to the colorectal area, the cumulative incidence of adenomas by age 45 years was statistically significantly higher than among siblings ARTICLE (P ¼ .03), and higher than among survivors without radiotherapy to the colorectal area, though this difference was not statistically significant (P ¼ .07).
Multivariable Cox Regression Analyses Colorectal Adenoma
We then performed multivariable Cox regression analyses to evaluate the role of concomitant characteristics and exposures ( 
Indications for Colonoscopy
We obtained medical information regarding diagnostic testing preceding colorectal adenoma diagnosis for 42 of 78 cases (Supplementary Table 5 , available online). Seventeen adenoma patients had a colonoscopy ordered for abdominal symptoms indicative of colorectal tumors. For another 17 individuals, the adenoma was discovered during medical surveillance in highrisk groups. In eight patients, adenoma represented an accidental finding on imaging/colonoscopy ordered for reasons other than a suspected colorectal tumor. The findings were essentially similar for patients with and without a history of colorectal RT exposure. Results of treatment-related risk factors in multivariable Cox models did not materially change when excluding 17 individuals who received surveillance colonoscopies (not shown). Figure 3 , available online). Four CRC patients (30.7%) had received abdominopelvic radiotherapy, five (38.5%) had received other radiotherapy (including one with spinal radiotherapy), and most had some form of prior chemotherapy (n ¼ 11, 84.6%). Four of 13 (30.8%) CRC cases had received alkylating agents; none had received platinum agents. Moreover, nine of 13 patients (69.2%) with subsequent CRC also developed an adenoma; seven of them had a synchronous diagnosis of first adenoma and CRC.
Discussion
Our data show that childhood cancer survivors treated with radiotherapy to the colorectal area-including TBI-are at increased risk of adenomas compared with a sibling comparison group and that childhood cancer survivors are at a more than threefold increased risk of CRC compared with the general population. To our knowledge, this is the first study to assess the risk of and risk factors for histologically confirmed colorectal adenomas among childhood cancer survivors, based on a cohort not subject to systematic colorectal tumor screening with near-complete treatment characterization and follow-up up to January 2017. Moreover, adenoma risk factors include prior treatment with the chemotherapeutic agents cisplatin and procarbazine, a personal history of hepatoblastoma (FAP related), and a family history of early-onset CRC.
We showed an increased risk of CRC in our study group compared with the general population. Over the past decade, several high-quality follow-up studies among very long-term childhood (1, 2, 19) and adult (4, (20) (21) (22) cancer survivors reported elevated CRC risk consistent with our results, in particular among survivors of Wilms' tumor and Hodgkin lymphoma after high-dose abdominal radiotherapy (2, 4, 19) . As most CRCs are preceded by adenomas in the general population (9), we hypothesized that risk factors for CRC and adenoma are similar. Conversely, Brenner and colleagues estimated from a CRC screening study among older citizens that less than half of all adenomas advance to CRC during a life-time, including decreasing conversion rates with attained age (23) .
We found that survivors with previous abdominopelvic radiotherapy/TBI were at increased risk of adenomas compared with survivors treated otherwise, and in comparison with siblings. The lack of radiation dose response is consistent with Variables that were evaluated in multivariable analysis but were not statistically significantly associated with adenoma risk and thus not included in this table were volume of colorectal area in radiation field, maximum prescribed dose to the colorectal area (and interaction between volume and prescribed dose) (see Supplementary Table 4 , available online, for more details), carboplatin, childhood cancer diagnosis of medulloblastoma, etoposide, teniposide, mercaptopurin, and hematopoietic cell transplantation. Although hematopoietic cell transplantation was statistically significantly associated with adenoma risk in univariate analysis, this variable did not statistically significantly increase adenoma risk in multivariable analysis when total body irradiation was also in the model. As total body irradiation was still statistically significantly elevated when both variables were in the model, we choose to include total body irradiation in the final model rather than hematopoietic cell transplantation. An indicator variable for a childhood cancer diagnosis of hepatoblastoma was included because hepatoblastoma survivors have a highly increased risk of familial adenomatous polyposis (FAP). All four hepatoblastoma cases had a confirmed genetic diagnosis of FAP. CI ¼ confidence interval; Gy ¼ Gray;
HR ¼ hazard ratio. †Test for trend in continuous dose variable among exposed survivors. ‡Includes seven survivors (two CRA cases) who received both abdominopelvic radiotherapy (all seven had spinal radiotherapy) and total body irradiation. §Categories based on median dose among exposed adenoma cases. kDefined as having a first-degree relative affected by colorectal cancer before age 50 years. findings from the only other large study on ionizing radiation and adenoma risk, among Atomic Bomb survivors, who were exposed to much lower median radiation doses (24) . Several factors may contribute to the lack of radiation dose response for adenoma in this exploratory study: the rather limited range of cumulative maximum prescribed dose to the colorectal region (median ¼ 30.0 Gy, interquartile range ¼ 20.0-35.2 Gy), the fact that we used surrogates for true absorbed colon/rectum dose, and the limited number of adenoma cases with any radiotherapy exposure to the abdomen. The lack of volume effects may be related to the validity of our proxy (ie, treatment field-based estimation) for exposed colorectal volume; nonetheless, this carefully constructed variable, in combination with treatment dose, provides a more detailed classification of colorectal radiation exposure than used in most other large-scale cohort studies of second tumor risk.
In our cohort, six survivors had more than 10 adenomas, including two cases after abdominopelvic radiotherapy/TBI. All TBI patients underwent HCT, and we hypothesize that HCTrelated factors other than ionizing radiation exposure might contribute to the high excess risk, such as immune dysregulation or closer medical follow-up among HCT survivors, who are at substantial risk for chronic health problems (25, 26) . Most patients with TBI have received an allogeneic HCT including intense treatment regimens. Despite rigorous adjustment for single agents, some residual confounding may persist.
Previous cisplatin treatment, a putative risk factor for gastrointestinal tract cancer (1) , is associated with adenoma risk in our study. Although cisplatin was often part of hepatoblastoma and bone sarcoma treatment, our sensitivity analyses excluding hepatoblastoma and LFS-associated childhood cancer types suggested that only a small part of the cisplatin-associated risk could be attributed to LFS-associated genetic susceptibility. We also observed a statistically significantly increased risk of adenomas for the alkylating agent procarbazine, but only among survivors without prior abdominopelvic radiotherapy or TBI. Previous childhood cancer survivor studies implicated alkylating agent exposure as a risk factor for CRC (2) and procarbazine as a risk factor for any gastrointestinal tract cancer (53% CRC) (1). Associations with procarbazine have been reported among survivors of young adult cancer (27) (28) (29) .
In our study, four (8%) of a total of 52 hepatoblastoma survivors developed an adenoma, all four with a confirmed FAP diagnosis and including three with multiple adenomas. This constellation of tumors constitutes well-established FAP features (17, 30, 31) . It is conceivable that other cohort members with adenoma have genetic syndromes associated with increased colon tumor risk, such as LFS (32) ; based on available data, this was not apparent.
A major strength of our study is the large cohort size with joint availability of detailed individual treatment information and objective data on histologically confirmed adenomas from linkage to the nationwide registry of histo-and cytopathology (PALGA) for more than 95% of the study population (14) . Furthermore, the sibling comparison group enables assessment of global excess risk.
Limitations include the slight chance of false-positive findings with the PALGA linkage on family name, sex, and birth date due to administrative twins. Also, as PALGA attained nation-wide coverage in 1990, we left-truncated the follow-up on January 1, 1990 . Only 9% of potential person-years prior to 1990 were missed, predominantly among young individuals (age < 30 years) (Supplementary Figure 1, available online) . Second, for adenoma cases, we sought information on colonoscopies. This was not attempted for more than 5700 survivors without an adenoma. Although some detection bias may exist, the extent is likely small: Evidence-based DCOG-LATER follow-up recommendations, with adherence in all seven follow-up clinics, do not include active colorectal tumor surveillance, eliminating screening bias. Moreover, less than 2% of cohort members are eligible yet for the population-based CRC screening program for people age 55 to 75 years, which is being implemented during 2014-2019 (33) . Therefore, the lack of systematic colorectal tumor surveillance implies that not all incident, asymptomatic adenomas will be known. On the other hand, survivors treated with abdominopelvic radiotherapy and/ or TBI are under more frequent late effects clinic surveillance and may experience more abdominal complaints than those treated with chemotherapy only, and may receive more abdominal ultrasounds. This diagnostics tool is not suitable to detect colorectal tumors whereas colonoscopies are mainly used in case of symptoms indicative of tumors or inflammatory conditions. Accordingly, few adenomas (8/42 ¼ 19%) were discovered incidentally on imaging or during medical follow-up for symptoms other than a suspected colorectal tumor, without clear differences between those with and without abdominopelvic radiotherapy/TBI; a major bias is thus quite unlikely (Supplementary Table 5 , available online). Finally, a note of caution is in place with regard to the findings for specific chemotherapy agents. It is well-recognized that treatments are not homogeneously distributed in mixed childhood cancer survivorship cohorts (13, 34) . As we did not demonstrate clear dose response trends, we cannot exclude the possibility that some of these agents in fact are surrogates for other factors not captured otherwise.
Further studies are needed to validate our findings; however, this is challenging in most settings as they require joint access to individual treatment data and objective sources for assessment of benign tumors in large cohorts (or nested studies therein). As a majority of our cohort has not yet reached the ages at which incidence of colorectal tumors in the general population is high, continued observational studies of colorectal tumors in childhood cancer survivors are warranted.
Finally, detection of early-stage colorectal tumors decreases CRC-specific mortality (6) . Survivors with a family history of early-onset CRC, a group for whom CRC surveillance was implemented (35) , were at greater than 20-fold increased risk of developing an adenoma. In our study, almost 70% of the CRC patients also had an adenoma, often detected around the CRC diagnosis date, which is suggestive of an adenoma-carcinoma sequence in CRC pathogenesis; this hypothesis needs confirmation. Screening among asymptomatic high-risk survivors is being considered (1-3) . At present, the US Children's Oncology Group is the only guideline group recommending a colonoscopy at a minimum of every five years for survivors who received 30 Gy or more abdominopelvic or spinal radiotherapy, from 10 years after radiation or starting at age 35 years, whichever occurs last (36) . National guideline groups have gathered in the International Guideline Harmonization Group (IGHG) to evaluate and harmonize recommendations for surveillance of late effects after treatment for childhood and young adult cancer based on evidence-based methods (37-39). IGHG's work on CRC surveillance is scheduled to start shortly.
In conclusion, we provide new evidence for excess risk of histologically confirmed colorectal adenomas among childhood cancer survivors. Treatment-related risk factors for adenoma were abdominopelvic radiotherapy, TBI/HCT, cisplatin, and procarbazine. Adenoma risk was strongly increased in hepatoblastoma survivors (FAP related) and in survivors with a family history of early-onset CRC, as expected. A full benefit-vs-harm evaluation of CRC screening among high-risk cancer survivors is warranted.
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